Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.31 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12609785 | 0.74 | CYP3A4 (0.40) | CYP3A4CYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL12609784 | 0.74 | CYP3A4 (0.40) | CYP3A4CYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6342722 | 0.72 | MAPT (0.36) | GAASMN1; SMN2 | |
| SCHEMBL6342726 | 0.72 | MAPT (0.36) | GAASMN1; SMN2 | |
| SCHEMBL6337763 | 0.72 | SSTR4 (0.41) | — | |
| SCHEMBL4539402 | 0.71 | CA2 (0.35) | — | |
| SCHEMBL25865687 | 0.68 | ADRB2 (0.37) | CYP3A4 | |
| SCHEMBL9178986 | 0.68 | KDM4E (0.39) | CYP2D6SLC6A4SLC6A3KCNH2GAA | |
| SCHEMBL6333201 | 0.68 | MAPT (0.36) | CYP2D6SMN1; SMN2 | |
| SCHEMBL7708906 | 0.68 | ADRB3 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6939867-B2 | Phenyl sulfamide derivatives as dietetics, antidiabetics, and hypotensive agents | PFIZER INC. (US) | 2005-09-06 | — | — | US | disclosed |
| US-20020128247-A1 | Beta3 agonists and uses thereof | DOW ROBERT L (US) | 2002-09-12 | — | — | US | disclosed |
| EP-1236723-A1 | Sulfamide derivatives useful as beta3 agonists and pharmaceutical uses thereof | Pfizer Products Inc. (US) | 2002-09-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128247-A1 | Beta3 agonists and uses thereof | ADRB3, ADRB1, ADRB2 | CYP3A4 1316/4885CYP2D6 1970/4885SLC6A2 161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.